Matthew D Galsky

Summary

Affiliation: US Oncology
Country: USA

Publications

  1. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
  2. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
  3. ncbi Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY 10029, USA
    Clin Genitourin Cancer 9:27-30. 2011
  4. ncbi Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 10:15-20. 2012
  5. ncbi Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 118:5947-54. 2012
  6. ncbi Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
  7. ncbi Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Department of Medicine, Director of Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    CA Cancer J Clin 62:299-308. 2012
  8. ncbi Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine, Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 29:2432-8. 2011
  9. ncbi A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Joshua J Meeks
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 62:523-33. 2012
  10. ncbi Overcoming castration resistance in prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Urol 22:167-74. 2012

Detail Information

Publications38

  1. ncbi Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  2. ncbi Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:549-55. 2007
    ..The safety and activity of a dose-dense carboplatin-based regimen in this patient population were explored...
  3. ncbi Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine Tisch Cancer Institute, New York, NY 10029, USA
    Clin Genitourin Cancer 9:27-30. 2011
    ..We retrospectively evaluated the activity of satraplatin in patients with cisplatin or carboplatin-refractory urothelial carcinoma and demonstrated lack of significant antitumor activity in this population...
  4. ncbi Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 10:15-20. 2012
    ..We sought to determine the impact of using the CKD-EPI equation for estimating renal function on cisplatin eligibility...
  5. ncbi Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy
    Alexander C Small
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Cancer 118:5947-54. 2012
    ..Reasons may include poor functional status, comorbidities, and patient preference. To the authors' knowledge, the prevalence and characteristics of this population have not previously been described...
  6. ncbi Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Joan and Sanford Weill Medical College of Cornell University, New York, NY 10021, USA
    Invest New Drugs 25:265-70. 2007
    ..The purpose of this single-center phase II study was to determine the activity of pemetrexed administered as second-line therapy in patients with advanced urothelial carcinoma...
  7. ncbi Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Department of Medicine, Director of Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    CA Cancer J Clin 62:299-308. 2012
    ....
  8. ncbi Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy
    Matthew D Galsky
    Mount Sinai School of Medicine, Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    J Clin Oncol 29:2432-8. 2011
    ..The purpose of this review is to define unfit patients and to identify treatment options for this subgroup of patients...
  9. ncbi A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Joshua J Meeks
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 62:523-33. 2012
    ..Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC...
  10. ncbi Overcoming castration resistance in prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA
    Curr Opin Urol 22:167-74. 2012
    ....
  11. ncbi Trends in the use of cytoreductive nephrectomy in the United States
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Genitourin Cancer 10:159-63. 2012
    ..However, first-line systemic therapy for mRCC changed in 2005 with FDA approval of VEGFR TKIs. We evaluated the patterns of use of CyNx from 2000 to 2008...
  12. ncbi The integration of chemotherapy and surgery for bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Natl Compr Canc Netw 3:45-51. 2005
    ..This review summarizes the available literature addressing the role of pelvic lymphadenectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy in the management of patients with muscle-invasive transitional cell carcinoma of bladder...
  13. ncbi Patient selection for phase II trials
    Guru Sonpavde
    Texas Oncology, P A, Dallas, Texas, USA
    Am J Clin Oncol 32:216-9. 2009
    ..Such trials may be superior guides to select regimens for further development than trials that are single-center based with favorable populations...
  14. ncbi Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
    Guru Sonpavde
    Texas Oncology, Baylor College of Medicine, Houston, TX 77598, USA
    Lancet Oncol 11:861-70. 2010
    ..A multidisciplinary approach is necessary to make therapeutic advances. This review discusses current second-line therapy and emerging drugs for advanced transitional-cell carcinoma...
  15. ncbi Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy
    Robert Jotte
    Rocky Mountain Cancer Centers, 10103 Ridgegate Pkwy G 01, Lone Tree, CO 80124, USA
    J Clin Oncol 29:287-93. 2011
    ..This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small-cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy...
  16. ncbi Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer
    Matthew D Galsky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1439-46. 2005
    ..To evaluate the antitumor activity and safety of the epothilone B analog, ixabepilone, with or without estramustine phosphate (EMP), in chemotherapy-naive patients with progressive castrate metastatic prostate cancer...
  17. ncbi Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics
    Matthew D Galsky
    Translational Oncology Program, US Oncology Research, Dallas, TX, USA
    Invest New Drugs 28:194-8. 2010
    ..To describe a phase II study design to evaluate the activity of novel anti-cancer agents that focuses on molecular pathogenesis rather than tumor histology...
  18. ncbi Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials
    Thomas E Hutson
    Genitourinary Oncology Program, Texas Oncology, PA, Baylor Sammons Cancer Center, Dallas, TX 75246, USA
    Clin Genitourin Cancer 5:S31-9. 2006
    ..Combinations of these agents are being evaluated. Clinical trials designed to further assess these and other agents need to be vigorously supported...
  19. ncbi Current optimal chemotherapy for advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research and Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA
    Expert Rev Anticancer Ther 8:51-61. 2008
    ..The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances...
  20. ncbi Novel agents for muscle-invasive and advanced urothelial cancer
    Guru Sonpavde
    US Oncology Research, Baylor College of Medicine, Houston, TX 77598, USA
    BJU Int 101:937-43. 2008
    ..Recent and ongoing trials of novel chemotherapeutic and biologic agents are reviewed...
  21. ncbi Outcomes and prognosis in advanced renal cell carcinoma
    Matthew D Galsky
    Genitourinary Oncology Program, US Oncology Research, Las Vegas, Nevada, USA
    Expert Rev Anticancer Ther 7:839-45. 2007
    ..This review will focus on studies that define the outcome and prognosis in advanced renal cell carcinoma...
  22. ncbi Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer
    Guru Sonpavde
    Genitourinary Oncology Program, U S Oncology Research, Houston, Texas, USA
    Cancer 110:2628-39. 2007
    ..Recent and ongoing studies of neoadjuvant therapy followed by prostatectomy were reviewed...
  23. ncbi The emerging role of circulating tumor cell detection in genitourinary cancer
    Alexander C Small
    Division of Hematology Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Urol 188:21-6. 2012
    ..The potential clinical applications of circulating tumor cells include early diagnosis, disease prediction and prognosis, and selection of appropriate therapies...
  24. ncbi Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
    Matthew D Galsky
    Mount Sinai Medical Center Tisch Cancer Institute, 1 Gustave L Levy Place, New York, NY 10029, USA
    Invest New Drugs 30:695-701. 2012
    ..To explore the activity of lapatinib with a novel trial design focused on the drug target rather than on histology...
  25. ncbi Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC)
    Che Kai Tsao
    Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    BJU Int 110:1580-8. 2012
    ....
  26. ncbi The role of taxanes in the management of bladder cancer
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Oncologist 10:792-8. 2005
    ....
  27. ncbi Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Matthew D Galsky
    Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 26:2147-54. 2008
    ..This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704...
  28. ncbi Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer
    William K Oh
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Urology 78:626-30. 2011
    ..To evaluate clinical activity and safety of retaspimycin hydrochloride (IPI-504) in patients with castration-resistant prostate cancer (CRPC)...
  29. ncbi A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study
    Robert W Ross
    Division of Solid Tumor Oncology, Department of Medicine, Dana Farber Cancer Institute, Boston, MA, USA
    Lancet Oncol 13:1105-13. 2012
    ..Survival for patients with castration-resistant prostate cancer is highly variable. We assessed the effectiveness of a whole-blood RNA transcript-based model as a prognostic biomarker in castration-resistant prostate cancer...
  30. ncbi Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Atreya Dash
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:506-13. 2006
    ..This finding is most striking in the elderly. Better selection of patients who may safely receive cisplatin and more effective regimens devoid of cisplatin are required to optimize outcomes in this group of patients...
  31. ncbi Bladder cancer: current management and opportunities for a personalized approach
    Matthew D Galsky
    Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 77:587-96. 2010
    ..This review will discuss bladder cancer as a paradigm for the development of personalized cancer medicine, focusing on recent efforts, current challenges, and future opportunities...
  32. ncbi Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer
    Che Kai Tsao
    Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Clin Med Insights Oncol 5:163-9. 2011
    ..In this review, we examine the clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer, as well as rationale and direction of future therapeutic investigation...
  33. ncbi Violaceous exanthem as a manifestation of metastatic prostate cancer in skin
    Susan F Slovin
    Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 67:420. 2006
  34. ncbi Problems with the randomized discontinuation design
    Guru Sonpavde
    J Clin Oncol 24:4669-70; author reply 4670-1. 2006
  35. ncbi Germ-cell tumors
    Varuni Kondagunta
    N Engl J Med 357:1773; author reply 1773-4. 2007
  36. ncbi Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
    Matthew D Galsky
    J Clin Oncol 23:4823-6. 2005
  37. ncbi A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy
    Jonathan E Rosenberg
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Cancer 106:58-62. 2006
    ..Clinical cross-resistance of ixabepilone and taxanes in HRPC is unknown...
  38. ncbi Trial design for metastatic castration-resistant prostate cancer
    Guru Sonpavde
    J Clin Oncol 26:3647-8; author reply 3648-9. 2008